At Lykos Therapeutics, our mission is to transform the way mental health is treated. We aspire to challenge the status quo through the development of novel therapies and therapeutic approaches to treat mental health conditions. With 30+ years of experience researching psychedelic-assisted therapies, we remain focused on following rigorous science from which we can develop and commercialize novel treatment options. 

Founded in 2014 by the non-profit Multidisciplinary Association for Psychedelic Studies (“MAPS”), we are a for-profit public benefit corporation (“PBC”). As a PBC, we consider the impact of our decisions on society just as we think about financial implications. Everything we do is looked at through a public benefit lens. To learn more, visit us at www.lykospbc.com. 

Life Sciences

Therapeutics

Lykos Therapeutics (formerly MAPS PBC)

Amy Emerson

E. Blair Clark-Schoeb

Allison Rosenthal

William Stewart

Michelle Lacy

Kacy Hutchison

Andrew Septimus

Dr. Berra Yazar-Klosinski

Berra Yazar - Klosinski

Michael Mullette

Joy Sun Cooper

Blair Clark - Schoeb

The Regulatory Affairs and Quality Assurance team at Lykos Therapeutics ensures that the development and commercialization of innovative therapies comply with regulatory standards and quality practices. This team plays a critical role in obtaining and maintaining approvals from regulatory bodies, overseeing clinical trial compliance, and implementing quality management systems to guarantee the safety and efficacy of new treatments for mental health conditions.

Regulatory Affairs and Quality Assurance

Clinical Research and Development

Financial and Administrative Support

Leadership Team

Regulatory Affairs and Quality Assurance

About

Team members

Other teams at Lykos Therapeutics (formerly MAPS PBC)

Clinical Research and Development

Financial and Administrative Support

Leadership Team